“These data indicate a role for PD-1 as a checkpoint that negatively controls CD30 expression in T reg cells to limit their suppressive function,” they noted. “In the absence of PD-1, an ...

T cell therapy, zilovertamab vedotin in relapsed or refractory (R/R) LBCL, and optimal dosing of AFM13 plus AlloNK in R/R ...

Enhanced expression of alternate checkpoint proteins, such as CD30, in Tregs drives this resistance. Combining anti-PD1 with anti-CD30 therapy overcomes resistance and may benefit other solid cancers.

Terbium-161, when linked to antibodies targeting the CD30 receptor, delivers highly localized radiation to lymphoma cells, effectively killing them while sparing healthy tissue.

If I’d gone flat after my mastectomy, I might be healthy now, but my breast implants led to more cancer, heart failure and years of pain.

In the paper they describe how targeting one of these immune suppressive proteins called CD30, can rescue, or overcome, checkpoint therapy resistance in skin cancer. As an opportunity for future ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised ...

In an announcement posted on June 24, the beloved CopperDog made the public aware of several changes coming to the classic ...

Takeda has received approval from the European Commission (EC) for its Pfizer-partnered blood cancer drug Adcetris (brentuximab vedotin). The drug has been approved in combination with the ...

The absence of PD-1 expression could induce CD30 expression, thereby enhancing T reg function and tumor escape, suggesting that CD30 might be a therapeutic target in cases of anti-PD-1 resistance.

A team of Newcastle University experts have discovered a new way to treat cancers that have proved hard to tackle previously. The scientists, led by Dr Shoba Amarnath, have been working on treatment ...